NCT03465592View on ClinicalTrials.gov

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2029

Conditions
SarcomaSolid Tumor, AdultSolid Tumor, Childhood
Interventions
DRUG

Nivolumab

Administered IV

Trial Locations (4)

10467

RECRUITING

Albert Einstein College of Medicine, Children's Hospital at Montefiore, The Bronx

10595

RECRUITING

New York Medical Center/ Maria Fareri Children's Hospital, Valhalla

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

33701

ACTIVE_NOT_RECRUITING

Johns Hopkins All Children's Hospital, St. Petersburg

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03465592 - Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | Biotech Hunter | Biotech Hunter